Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of cadonilimab versus sugemalimab as consolidation therapy after concurrent or sequential chemoradiotherapy in unresectable locally advanced non-small cell lung cancer
CTR20243422Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing cadonilimab consolidation with sugemalimab consolidation (2 arms). Primary endpoints: Grade 3 or higher pneumonitis incidence, 6-month progression-free survival rate and 1 more. Started Nov 2024; status: active.
02
Drugs
cadonilimabsugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243422.